There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Alnylam Pharma (NASDAQ:ALNY) and Supernus Pharmaceuticals (NASDAQ:SUPN) with bullish sentiments.
Alnylam Pharma (ALNY)
B.Riley FBR analyst Madhu Kumar reiterated a Buy rating on Alnylam Pharma yesterday and set a price target of $230. The company’s shares opened today at $86.40, close to its 52-week low of $84.48.
“This morning, 10/4, Alnylam Pharmaceuticals (ALNY) announced additional Phase I/II results for glycolate oxidase 1 (GO1) RNAi drug lumasiran for primary hyperoxaluria type 1 (PH1) at the Nephrology (ESPN) meeting in Antalya, Turkey (the presentation can be found here). ALNY further announced the start of the Phase III ILLUMINATE-A trial of lumasiran in PH1, for which top-line results are expected in late-19.”
According to TipRanks.com, Kumar is a 5-star analyst with an average return of 21.0% and a 47.5% success rate. Kumar covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Arbutus Biopharma Corporation, and Clementia Pharmaceuticals Inc.
Alnylam Pharma has an analyst consensus of Strong Buy, with a price target consensus of $146.77, representing a 69.9% upside. In a report issued on September 28, Cantor Fitzgerald also initiated coverage with a Buy rating on the stock with a $135 price target.
See today’s analyst top recommended stocks >>
Supernus Pharmaceuticals (SUPN)
In a report released yesterday, David Buck from B.Riley FBR reiterated a Buy rating on Supernus Pharmaceuticals, with a price target of $68. The company’s shares opened today at $48.46.
“We reiterate our Buy rating and $68 PT for Supernus (SUPN) shares. We recently met with the company and and we note (1) potential for acceleration for Oxtellar XR (epilepsy) with a potential December monotherapy FDA approval and 2019 re-launch, (2) updates for SPN-812 (non-stimulant 1Q19 release of Phase III results, and (3) read-out for SPN-810 impulsive aggression by 1Q19 and mid-2019 for two Phase III trials. We continue to expect attractive growth from in-line drugs Trokendi XR (epilepsy/migraine) and Oxtellar XR (epilepsy) and we expect 3Q18 revenues to meet or exceed our forecasts/consensus. Going forward we do moderate our Trokendi XR revenue forecast for 2019E from $401.5M to $391.4M for Y/Y growth of 24.8% versus consensus of $366.5M.”
According to TipRanks.com, Buck is a 4-star analyst with an average return of 14.5% and a 63.1% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Amag Pharmaceuticals.
Currently, the analyst consensus on Supernus Pharmaceuticals is a Strong Buy with an average price target of $57.40, a 18.4% upside from current levels. In a report released yesterday, Cantor Fitzgerald also maintained a Buy rating on the stock with a $56 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.